



## **NWT Influenza Program Vaccine Administration Summary 2023-2024**

This document acts as a quick reference for health care providers (HCPs) who will be administering the influenza vaccine in the NWT.

In order to administer vaccines in the NWT, HCPs must be competent as per the clinical practice information notice:

[#152: NWT Mandatory Education Program on Immunization Competency.](#)

**This document does not replace the Canadian Immunization Guide, the National Advisory Committee on Immunization (NACI) statement, or the vaccine product monographs. It is the vaccine administrator's responsibility to ensure they have reviewed the most current documents included in this influenza package. If there is a discrepancy between the NACI statement and the product monograph, please follow the NACI statement.**

1. [Canadian Immunization Guide](#)
2. [NACI Statement on Seasonal Influenza Vaccine for 2023-2024](#)
3. [2023 Vaccine Product Monographs: FLUZONE QIV and FLUZONE QIV HD](#)

| Product           | FLUZONE® Quadrivalent (QIV)<br>Sanofi Pasteur<br>Multi-Dose Vial   | FLUZONE® Quadrivalent (QIV) High Dose (HD)<br>Sanofi Pasteur<br>Single-Dose Prefilled Syringe<br><b>Preferred vaccine for individuals 65 years and older living in Long-Term Care Facilities</b>                                 |
|-------------------|--|--|
| Component Viruses | <ul style="list-style-type: none"><li>• A/Victoria/4897/2022(H1N1)pdm09-like strain</li><li>• A/Darwin/9/2021 (H3N2)-like strain</li><li>• B/Austria/1359417/2021-like strain</li><li>• B/Phuket/3073/2013-like strain</li></ul> | <ul style="list-style-type: none"><li>• A/Victoria/4897/2022(H1N1)pdm09-like strain</li><li>• A/Darwin/9/2021 (H3N2)-like strain</li><li>• B/Austria/1359417/2021-like strain</li><li>• B/Phuket/3073/2013-like strain</li></ul> |

| Product                           | FLUZONE® QIV   | FLUZONE® QIV HD                     |
|-----------------------------------|--|-------------------------------------|
| Vaccine Type                      | Inactivated split virus  |                                     |
| Antigen Amount                    | 15mcg of each strain per 0.5mL dose  | 60mcg of each strain per 0.7mL dose |
| Adjuvant                          | No   | No                                  |
| Age Indications                   | 6 months and older   | 65 years and older                  |
| Route of Administration           | Intramuscular  | Intramuscular                       |
| Dose                              | 0.5mL/influenza season   | 0.7mL/influenza season              |
| Booster                           | For children ages 6 months-9 years who are receiving the vaccine for the <b>first time</b> , a booster is required. The booster dose should be given a minimum of 4 weeks from the first dose.   | N/A                                 |
| Contraindications<br>(NACI, 2023) | <p><b>Egg allergy is not a contraindication for influenza vaccination (NACI, 2023).</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylactic reaction to any components of the influenza vaccine (excluding egg allergies).</li> <li>• Individuals who developed Guillain-Barre Syndrome (GBS) within 6 weeks of a previous influenza vaccine where another cause was not determined.</li> </ul> |                                     |

| Product  | FLUZONE® QIV  | FLUZONE® QIV HD  |
|--|---|--|
| <b>Precautions</b><br>(NACI, 2023)   | <p>The potential risk of influenza must be balanced against the risk of vaccine administration.</p> <ul style="list-style-type: none"> <li>Influenza vaccine should be postponed in people with <b>serious acute illnesses</b> until symptoms have resolved.</li> <li>Influenza vaccination <b>should not</b> be delayed due to mild or moderate acute illnesses (with or without fever). More information can be found in the Canadian Immunization Guide's chapter on <a href="#">Contraindications and precautions associated with specific conditions: Acute illness</a>.</li> <li><a href="#">Guidance on the use of influenza vaccine in the presence of COVID-19</a>.</li> </ul> |  |
| <b>Common Side Effects</b><br><br>For a complete list of side effects please refer to the vaccine product monograph. | Most reactions resolve within 3 days: <ul style="list-style-type: none"> <li>Pain, redness and swelling at the injection site.</li> <li>Headache, muscle and joint pain, fever, and/or general malaise.</li> <li>Children under 3 may experience irritability, drowsiness, appetite loss, and vomiting.</li> </ul>  | Reported reactions were slightly higher with the HD vaccine compared to the standard dose vaccine however most reactions were mild and resolved within 3 days. <ul style="list-style-type: none"> <li>Pain, redness and swelling at the injection site.</li> <li>Headache, muscle and joint pain, fever and/or general malaise.</li> </ul> |
| <b>Are there antibiotics, gelatin, or latex present in the vaccine?</b>  | No  |  |
| <b>Egg Protein</b>   | Yes   |  |
| <b>Thimerosal</b>  | Pre-filled syringe: No<br>Multi-dose vial: Yes  | No   |
| <b>Other Non-Medicinal Ingredients</b>   | Sodium phosphate-buffered, isotonic sodium chloride solution, formaldehyde, and Triton® X-100.  |  |

### **Adverse Event Following Immunization (AEFI) Specific to Influenza Vaccine Product**

Any unexpected, serious event (an event that is not listed in the vaccine product monograph but may be related to immunization) must be reported within 24 hours of identification of the AEFI to the Office of the Chief Public Health Officer.

Completed [AEFI forms](#) may be sent by Secure File Transfer to [CDCU@gov.nt.ca](mailto:CDCU@gov.nt.ca) or by fax to (867)873-0442.

### **Co-Administration of Influenza Vaccine and COVID-19 Vaccine**

“Administration of COVID-19 vaccines may occur concurrently with (i.e., same day), or at any time before or after seasonal influenza immunization for those aged 6 months and older...the injection sites should be separated by at least 2.5cm (1 inch)”  
[NACI, 2023](#) (p.7)

#### **Reference List:**

Government of Canada Drug Product Database online query for vaccine product monographs

[Fluzone QID and Fluzone QID HD](#)

Government of the Northwest Territories Seasonal Influenza Program Package for 2023-2024

[Seasonal Influenza Program Package 2023-2024 | HSS Professionals \(gov.nt.ca\)](#)

National Advisory Committee on Immunization Canadian Immunization (NACI): Statement on Seasonal Influenza Vaccine for 2023-2024:

[National Advisory Committee on Immunization: Canadian Immunization Guide Statement on Seasonal Influenza Vaccine for 2023-2024](#)

Public Health Agency of Canada: Adverse Event Following Immunization form:

[Report of Adverse Events Following Immunization \(AEFI\) - Immunization & Vaccines - Public Health Agency of Canada](#)